Remote Monitoring for Interstitial Lung Disease
This study is testing different ways to monitor people with fibrotic interstitial lung disease (f-ILD) from home. This includes conditions like Idiopathic Pulmonary Fibrosis (IPF) and other types of lung fibrosis. You would use devices like a spirometer (to measure breathing), a pulse oximeter (to check oxygen levels), and/or a wireless scale, all connected to your phone. Researchers want to see which combination of these tools works best to detect important changes in your health. To join, you need to be 18 or older, speak English or Spanish, and have a UCSF diagnosis of a major ILD type. The study aims to find out how well these tools can spot new health events and how consistently people use them over 12 months. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 200 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would have an initial in-person visit and a final in-person visit at the UCSF clinic. Other follow-up visits at 3, 6, and 9 months will be done remotely via Zoom. You will use study-provided home monitoring devices weekly (spirometry for all, some also daily pulse oximetry and/or weekly weight measurements) and complete electronic questionnaires for 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for 12 months, with primary endpoints measured at Baseline and Month 12.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
At a glance
Conditions
NCT07673237
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Erica Farrand, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Detection rate of clinically significant ILD eventsBaseline, Month 12
Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months
- Time to detection of first ILD eventBaseline, Month 12
Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months.
- Adherence12 months
Adherence to remote monitoring protocol, defined as the proportion of measurements completed \>=67% of weeks with full data entry)
- Retention12 months
Primary: Participant retention at 12 months (target \>=80%)
- Data Completeness12 months
Data completeness, defined as \>85% of expected remote monitoring data points successfully transmitted